AstraZeneca Net Income 2006-2018 | AZN

AstraZeneca annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • AstraZeneca net income for the quarter ending September 30, 2018 was $0.431B, a 37.17% decline year-over-year.
  • AstraZeneca net income for the twelve months ending September 30, 2018 was $2.422B, a 31.62% decline year-over-year.
  • AstraZeneca annual net income for 2017 was $3.001B, a 14.23% decline from 2016.
  • AstraZeneca annual net income for 2016 was $3.499B, a 23.86% increase from 2015.
  • AstraZeneca annual net income for 2015 was $2.825B, a 129.12% increase from 2014.
AstraZeneca Annual Net Income
(Millions of US $)
2017 $3,001
2016 $3,499
2015 $2,825
2014 $1,233
2013 $2,556
2012 $6,240
2011 $9,917
2010 $8,053
2009 $7,544
2008 $6,130
2007 $5,595
2006 $6,063
2005 $4,724
AstraZeneca Quarterly Net Income
(Millions of US $)
Q3 2018 $431
Q2 2018 $350
Q1 2018 $340
Q4 2017 $1,301
Q3 2017 $686
Q2 2017 $477
Q1 2017 $537
Q4 2016 $1,842
Q3 2016 $1,014
Q2 2016 $-3
Q1 2016 $646
Q4 2015 $808
Q3 2015 $770
Q2 2015 $697
Q1 2015 $550
Q4 2014 $-321
Q3 2014 $254
Q2 2014 $796
Q1 2014 $504
Q4 2013 $-524
Q3 2013 $1,246
Q2 2013 $823
Q1 2013 $1,011
Q4 2012 $1,507
Q3 2012 $1,511
Q2 2012 $1,597
Q1 2012 $1,625
Q4 2011 $1,493
Q3 2011 $3,477
Q2 2011 $2,113
Q1 2011 $2,907
Q4 2010 $1,632
Q3 2010 $1,554
Q2 2010 $2,116
Q1 2010 $2,777
Q4 2009 $1,562
Q3 2009 $2,115
Q2 2009 $1,707
Q1 2009 $2,144
Q4 2008 $1,250
Q3 2008 $1,738
Q2 2008 $1,620
Q1 2008 $1,505
Q4 2007 $1,280
Q3 2007 $1,340
Q2 2007 $1,400
Q1 2007 $1,564
Q4 2006 $1,445
Q3 2006 $1,592
Q2 2006 $1,602
Q1 2006 $1,424
Q4 2005 $1,227
Q3 2005 $1,230
Q2 2005 $1,220
Q1 2005 $1,043
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $102.177B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $392.911B 18.42
Pfizer (PFE) United States $259.128B 14.61
Merck (MRK) United States $201.621B 17.47
Novartis AG (NVS) Switzerland $201.503B 17.22
AbbVie (ABBV) United States $132.506B 11.76
Eli Lilly (LLY) United States $121.525B 21.36
Sanofi (SNY) France $112.036B 13.87
Novo Nordisk (NVO) Denmark $106.636B 17.32
GlaxoSmithKline (GSK) United Kingdom $100.760B 13.54
Bristol-Myers Squibb (BMY) United States $87.355B 14.39